Innovation Pharmaceuticals Inc (IPIX)

[Lemoncat]

Because we thought B-ABSSSI was going to be partnered and be a slam dunk for phase 3 the following year. Lot's of comparisons to the $1B/year Cubicin (Dapto) had us thinking it would result in a lucrative partnership.

Also, right about that same time Kevetrin cured stage 4 cancer:

www.ipharminc.com/press-release/2016/11/16/cellceutix-reports-spleen-lesion-disappears-in-patient-with-metastatic-stage-4-ovarian-cancer-in-clinical-trial-of-anti-cancer-drug-kevetrin

So...we had a much stronger cash position and a better pipeline at the time. We were on a winning streak at the start of 2015, much exuberance, much credit to the future, etc. That needs to be rebuilt after the 2017/2018 string of defeats (Prurisol failure and the handling of it, the horrendous financing agreements, missed milestones, etc.)

Still awaiting a straight forward answer as to why we have been unwilling to partner B-ABSSSI. I know that is the reason I invested here in the first place. We have deduced that either we want to run the phase 3 ourselves because it is a certain victory, or it's because it will be held in reserve for the life of the patent and will generate no substantial revenue, or because we're waiting for real government incentives, etc.

This deal was a start, but without knowing the upfront payment it's not enough. Looking forward to additional deals with enough cash to really begin advancing the pipeline across the board. I think once the team delivers another partnership with better terms the market will afford us more credit for future potential.

AS was a good start Leo! Bring in some bigger fish now! REGN model it up.